MOTS-c
Also known as: MOTS-c, MOTSc, Mitochondrial ORF of the 12S rRNA type-c, MOTS
Mitochondria-derived peptide discussed for metabolic health and insulin sensitivity — genuinely interesting mechanism, and human evidence that is still almost entirely absent.
Substance family
Peptides used for tendon, gut and skin repair. Mechanisms are described and animal data exists; controlled human trials for these applications largely do not.
Effects on
Which outcomes this substance acts on — descriptive, not a recommendation.
Strain profile
Where this substance is most likely to hit — a rough orientation, individually dependent on dose, duration and predisposition.
This substance works against
Dosing & protocols by goal
Rough orientation ranges as reported in harm-reduction literature — not an individual treatment plan. Doses are individual and open-ended; frequency depends on the ester or half-life.
Metabolic support
ExperimentalDose
5–10 mg / week
Frequency
2–3× / week, subcutaneous
Cycle length
4–6 weeks, then a break
Common practice in the peptidepeptideA short chain of amino acids — the reason this whole category has to be injected. scene, not an established protocol. Dose in mg, unlike most peptides in this field — a point where confusion happens.
Medical use
MedicalDose
—
Frequency
—
Cycle length
—
No approved indication anywhere. What exists are cell culture and rodent studies plus observational data on natural MOTS-c levels in humans.
Side effect & countermeasure
Typical problems and what you can do to reduce harm — at a glance. Does not replace medical monitoring.
Problem
Human evidence essentially absent
Countermeasure
The mechanism is well described and the rodent data is genuinely interesting, but controlled human trials for this application do not exist. Anyone using it is relying on mechanism and extrapolation. That is worth knowing before spending money on it.
Problem
Effects on blood glucose
Countermeasure
MOTS-c improves insulin sensitivityinsulin sensitivityHow strongly the body responds to its own insulin — worsened by growth hormone and by some blood-pressure drugs. in animal models. Relevant for anyone already taking metformin or insulin — the effects can add. Check fasting glucose and HbA1c, particularly with pre-existing insulin resistance.
Problem
Dosing confusion between mg and µg
Countermeasure
MOTS-c is dosed in milligrams, while ipamorelin, BPC-157 and most peptidespeptidesA short chain of amino acids — the reason this whole category has to be injected. here use micrograms. Carrying over a µg habit underdoses by a factor of 1000. Check the vial and calculate the concentration before the first injection.
Problem
Uncertain product quality
Countermeasure
Only vendors with an independent HPLC/MS analysis certificate. Reconstitute with bacteriostatic water, store refrigerated, observe shelf life after reconstitution.
Problem
Overstated longevity claims
Countermeasure
MOTS-c levels decline with age, which is often presented as evidence that supplying it reverses ageing. The correlation is real; the causal claim is not established. Treat marketing language accordingly.
Overview
MOTS-c belongs to a class discovered only relatively recently: peptides encoded not in the cell nucleus but in mitochondrial DNA. Mitochondria produce energy, and it turns out they also send signals — MOTS-c is one of them.
The scientific interest is genuine. MOTS-c influences metabolism, insulin sensitivity and exercise capacity in animal models, and its levels in humans decline with age and are lower in people with type 2 diabetes.
The gap between that and its use as an injectable is worth stating plainly: the human data is observational. Almost nothing exists showing what happens when you inject it.
Mechanism of Action
MOTS-c is a sixteen-amino-acid peptide encoded in the mitochondrial genome. Under metabolic stress it moves to the cell nucleus, where it influences gene expression — a signalling path from the mitochondria to the nucleus.
Its central effect runs through the AMPK pathway, the same pathway metformin and exercise act on. AMPK is the cell's energy sensor: when activated, it promotes glucose uptake and fat oxidation and inhibits energy-storing processes. This is why MOTS-c is described as an exercise mimetic — the effects overlap with what training produces.
In rodents, MOTS-c improves insulin sensitivity, prevents diet-induced obesity and increases running capacity in older animals. Those findings are the entire basis of the interest in it.
The observational human data adds a second layer: MOTS-c levels fall with age and are lower in metabolic disease. This is often presented as though supplying it should reverse both. The correlation is documented; the causal direction is not established.
Typical Context
MOTS-c is used in the peptide scene for metabolic support, typically at five to ten milligrams weekly split across two or three injections, over four to six weeks.
None of this rests on human trial data. It rests on mechanism and rodent studies, which is a legitimate reason to be interested and not a legitimate reason to expect a specific result.
One practical detail matters: MOTS-c is dosed in milligrams. Most peptides in this field — ipamorelin, BPC-157, CJC-1295 — are dosed in micrograms. Anyone transferring a familiar habit here is off by a factor of a thousand in one direction or the other.
For anyone already managing insulin sensitivity with metformin, the overlap in mechanism is worth noting. Both act on AMPK, and the effects can add.
Side Effects & Risks
- Human evidence essentially absent for this application
- Effects on blood glucose, potentially additive with metformin or insulin
- Local reactions at the injection site
- Fatigue reported occasionally
- Uncertain product quality on the grey market
- Long-term safety in humans entirely uncharacterised
Blood Work & Monitoring
- Fasting glucose and HbA1c — the mechanism targets glucose metabolism directly
- Fasting insulin — for assessing insulin sensitivity
- Lipid profile (LDL, HDL, triglycerides)
- Liver values (ALT, AST, GGT) — as a baseline
Harm-Reduction Notes
- Dose in mg, not µg — check the vial before the first injection
- Relevant interaction with metformin and insulin; both act on overlapping pathways
- Only sources with an independent analysis certificate
- Reconstitute with bacteriostatic water, store refrigerated, observe shelf life
- Understand what the evidence base is: mechanism and rodent data, not human trials
- Age-related decline in MOTS-c is a correlation, not proof that supplying it helps
Legal status by region
Regulation differs considerably between jurisdictions and changes over time. This is a rough orientation, not legal advice — check the rules that apply where you are.
| Region | Regulatory status |
|---|---|
| United States | Not approved for human useSold as a research chemical; marketing for human consumption is unlawful. |
| EU / UK | No marketing authorisationNeither a medicine nor a supplement — no legal route for human use. |
| Most other jurisdictions | Unregulated grey areaPossession is legal in many places precisely because no framework covers it. That is not an indication of safety. |
| Competitive sport | ProhibitedListed by WADA where a relevant class applies. |